Chief Executive Officer
John P. Kelley joined our company as Chief Executive Officer in November 2013, and has served as a director since December 2013. Prior to joining our company, Mr. Kelley co-founded Phyxius Pharma, Inc. (“Phyxius”) and held the positions of Chief Executive Officer and Director from January 2010 until November 2013. Prior to Phyxius, Mr. Kelley served as President and Chief Operating Officer of The Medicines Company, a provider of medical solutions to hospitals, from December 2004 to December 2009 and as a director from February 2005 to December 2009. Prior to The Medicines Company, Mr. Kelley held a series of positions at Aventis Pharmaceuticals, Inc. (“Aventis”), an international pharmaceutical company. From September 2003 until September 2004, Mr. Kelley served as Senior Vice President, Global Marketing and Medical at Aventis, where he was accountable for worldwide brand management of Aventis’ core strategic brands and managed strategic alliances with partner companies. From September 2002 to September 2003, he served as Senior Vice President, Strategic Risk Officer for Aventis, advising the Management Board and Chief Executive Officer. From January 2000 to September 2002, Mr. Kelley served as Vice President, Head of Strategic Development of Aventis where he was responsible for leading the strategic planning process of the pharmaceutical division of Aventis as well as merger and acquisition activity. Prior to the formation of Aventis, he served as a Vice President, Commercial Director, U.S. at Hoechst Marion Roussel, Inc., a life sciences firm focused on pharmaceuticals and agriculture, from March 1998 through December 1999 and Mr. Kelley served as Vice President of Marketing of Hoechst Marion Roussel from 1995 to 1998. Mr. Kelley currently serves on the Board of Directors of Acorda Therapeutics. Mr. Kelley received a B.S. degree in Biology from Wilkes University and an M.B.A. from Rockhurst University.
Chief Financial Officer
Mr. Jebsen was named Interim Chief Executive Officer in August 2011, while retaining his role as Chief Financial Officer and Treasurer. He joined Oxygen Biotherapeutics as our Accounting Manager in April 2009 and was elected CFO in August 2009. Before joining Oxygen, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009. In addition, he held various positions, including Chief Ethics Officer, Senior Internal Auditor, and Senior Financial Analyst with RTI International, a non profit research and development organization, from January 2006 to February 2008. Mr. Jebsen holds a Master of Science in Accounting from East Carolina University and is a certified Public Accountant, licensed in North Carolina.
EVP of Regulatory Affairs
Dr. Hay has over 29 years pharmaceutical regulatory experience. Prior to joining the company Dr. Hay was a co-founder of Phyxius Pharma, Inc. where he served as Vice President of Regulatory Affairs. Previously, Dr. Hay lead positions in global regulatory affairs at The Medicines Company and Shire Pharmaceuticals. He spent the majority of his career at Bristol Myers Squibb where he advanced to Vice President, Global Regulatory Sciences. This experience spans drug development (Phase 1-4) in numerous therapeutic areas, including the development of novel biologics and new chemical entities. Dr. Hay’s experience has included responsibility for development projects in virtually all major cardiovascular classes, including development/registration programs for Capoten, Monopril, Avapro, Plavix, and Angiomax. Doug received his AB degree in Biology from University of California, Riverside, MS in biology at California State University, Long Beach, and PhD (physiology emphasis) from Northern Arizona University.
EVP, Legal Affairs, General Counsel, and Corporate Secretary
Ms. Hecox joined Oxygen as General Counsel in October 2009. She brings over a decade of experience in the pharmaceutical/biotech industry from prior positions with Becton Dickinson, eTrials Worldwide, Quintiles, and DSM Pharmaceuticals. Ms. Hecox holds a BS degree in Communications from the State University of New York and an MBA from East Carolina University. She received her JD degree from North Carolina Central University, graduating cum laude, and is admitted to the North Carolina State Bar.
EVP of Commercial and Business Operations
Mr. Randall has 33 years of pharmaceutical executive experience. Prior to joining the company, Mr. Randall co-founded Phyxius Pharma, Inc. in 2011 where he served as the Chief Commercial Officer. Previously, Mr. Randall served in many senior level executive positions within the pharmaceutical industry, including: Vice President of Commercial Operations at The Medicines Company; Vice President of US Diabetes Marketing at Sanofi-Aventis Pharmaceuticals; and Vice President of Sales at Aventis Pharmaceuticals. Prior to the formation of Aventis Pharmaceuticals in 2000, Mr. Randall served in several senior commercial roles at the former legacy companies (Hoechst Marion Roussel, Marion Merrell Dow, and Marion Laboratories) including: Director of Respiratory Marketing, Director of Cardiovascular marketing, Director of GI/CNS Marketing, Director of Distribution and Pharmacy Markets, and various sales management roles. Mr. Randall started his pharmaceutical career as a sales representative for Marion Laboratories, Inc. in 1982 after earning his B.S. in Pharmacy from the University of Rhode Island.